Dear Friend,
The future of CF has never looked brighter. The CF Foundation’s relentless pursuit of better todays and more tomorrows for people with CF, combined with the efforts of our extraordinary community, has resulted in significant treatment advances and changed the face of this disease. Despite extraordinary progress, there is still critical work to be done. We are committed to continuing to lead the way in the fight against CF.
Today, we are writing to announce our Path to a Cure, an ambitious agenda to accelerate treatments for the underlying cause of disease for all people with CF and ultimately deliver a cure. We are issuing a call to scientific innovators around the world to accelerate CF therapeutic development and intend to allocate half a billion dollars to fund proposals through 2025.
We are entering an age of unmatched scientific understanding and development of genetic-based therapies. Now is the time for a bold commitment to stimulate industry investment in CF to capitalize on the current pace of progress and draw these advances toward the people in our community who need them most.
| |
We are committed to ensuring every person with CF has a therapy for their underlying cause of disease, no matter their mutation, and eventually finding a cure for all. We also know that many people with CF urgently need better treatments to manage their disease today. We are aggressively funding research into new therapies with the potential to improve outcomes related to lung infections, CF disease affecting other parts of the body, lung transplantation, and other challenges associated with advanced disease.
The path forward will not be a straight line. We will confront twists and turns, new roads, and unforeseen obstacles as we tackle the scientific challenges before us. But to assure we reach our destination, we will seek to fund any research we believe holds promise, and we will not rest until CF stands for cure found.
Join us on this journey. Learn more about our commitment and the scientific path ahead.
Preston Campbell, MD
President and CEO
Michael Boyle, MD
SVP, Therapeutics Development
| |
|
|
|
|
